These results demonstrate sensitivity to FAK inhibition in some HNSCC tumors and also further demonstrate the potential clinical utility of combined IGF1R and Src inhibition for a subset of patients. This evidence concerns the gene IGF1R and head and neck squamous cell carcinoma.